GB223 / Walvax - LARVOL DELTA

Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults. (PubMed, BioDrugs) - P1 | "In this study, we demonstrated for the first time that a single subcutaneous injection of GB223, from 7 to 140 mg, is safe and well tolerated in healthy Chinese subjects. GB223 has a nonlinear pharmacokinetic profile, and sex was a potential covariate that may affect the absorption rate of GB223."

Clinical • Journal • NF-κβ

Newly added product (clinicaltrials.gov) - P1, Oncology

Pipeline update